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Ra]RaCl2 ), a radiopharmaceutical that delivers α-particles to regions of 
bone metastatic disease, has been proven to improve overall survival of men with metastatic castration 
resistant prostate cancer (mCRPC). mCRPC patients enrolled on the ADRRAD clinical trial are 
treated with a mixed field exposure comprising radium-223 (
223
Ra) and intensity modulated 
radiotherapy (IMRT). While absorbed dose estimation is an important step in the characterisation of 
wider systemic radiation risks in nuclear medicine, uncertainties remain for novel 




24-colour karyotyping was used to quantify the spectrum of chromosome aberrations in peripheral 
blood lymphocytes of ADRRAD patients at incremental times during their treatment. Dicentric 
equivalent frequencies were used in standard models for estimation of absorbed blood dose. To 
account for the mixed field nature of the treatment, existing models were used to determine the ratio 
of the component radiation types. Additionally, a new approach (M-FISHLET), based on the ratio of 
cells containing damage consistent with high-LET exposure (complex chromosomal exchanges) and 




Total IMRT estimated doses delivered to the blood after completion of mixed radiotherapy (after 37 
IMRT fractions and two [
223
Ra]RaCl2 injections) were in the range of 1.167 ± 0.092 and 2.148 ± 0.096 
Gy (dose range across all models applied). By the last treatment cycle analysed in this study (four 
[
223
Ra]RaCl2 injections), the total absorbed 
223
Ra dose to the blood was estimated to be between 0.024 
± 0.027 and 0.665 ± 0.080 Gy, depending on the model used. Differences between the models were 
observed, with the observed dose variance coming from inter-model as opposed to inter-patient 
differences. The M-FISHLET model potentially overestimates the 
223
Ra absorbed blood dose by 













The models presented provide initial estimations of cumulative dose received during incremental 
IMRT fractions and [
223
Ra]RaCl2  injections, which will enable improved understanding of the doses 
received by individual patients. While the M-FISHLET method builds on a well-established technique 
for external exposures, further consideration is needed to evaluate this method and its use in assessing 
non-targeted exposure by 
223
Ra after its localization at bone metastatic sites.  
 
[Insert graphical abstract] 
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Metastatic castration resistant prostate cancer (mCRPC) is an incurable condition. Prostate cancer has 
a strong predisposition to forming bone metastases, with upwards of 90% of patients with advanced 
disease being affected, often with bone as the only site of metastasis (1). As the general standard of 
care in the UK, patients with mCRPC are offered a number of life-prolonging therapies including 
chemotherapy, novel anti-hormonals and radium-223 dichloride ([
223
Ra]RaCl2). Recent advances in 
molecular radiotherapy have generated a great deal of interest, particularly the use of [
223
Ra]RaCl2 
after the landmark phase III trial ALSYMPCA (2-4) showed for the first time an overall survival 
advantage associated with [
223
Ra]RaCl2 treatment. Along with survival prolongation, this trial also 
demonstrated significant improvement in the quality of life by delaying the onset of symptomatic 
skeletal related events and alleviating pain. This led to FDA and EMA approvals and the widespread 
use of [
223
Ra]RaCl2 for symptomatic mCRPC (5, 6). 
223
Ra has a half-life of 11.43 days, decaying 
through creation of a succession of short-lived nuclides to stable 
207
Pb. During its decay chain, 
223
Ra 
emits four α and two β particles, with 94% of its decay energy released as high LET α-particles over a 
short track length of <100 µm (7, 8). When living tissue is exposed to 
223
Ra, this results in the 
localised induction of clustered DSB lesions which are difficult to repair, effectively leading to cell 









under the trade 
name of Xofigo (5). Once administered, [223Ra]RaCl2 immediately solubilises in the blood resulting in 
free 
223
Ra, which as a calcium mimetic, is cleared from the blood within 24 hours (h) (12) localising 
to areas of freshly mineralized bone. The uptake of 
223
Ra into high-turnover areas of bone is not 
dependent on a particular malignant signalling process. Thus, [
223
Ra]RaCl2 could be of benefit in a 
range of other malignancies which have a predisposition to forming bony metastases such as breast, 
lung, kidney and myeloma, including those with favourable long-term survival probability. Due to the 
short range of α-particles, this effective target cell kill also minimises direct α-particle exposure to 
non-target normal cells (7, 13-16). There is also evidence, however, that 
223












absorbed doses in sites adjacent to target bone metastases, including osteogenic cells and the red bone 
marrow (17-20). It has also been reported that additional biological responses via bystander effects 
may also occur (21). 
 
Currently, the number of studies which seek to understand the biological action of 
223
Ra in vivo in 
humans is limited (22), indeed, there remains a lack of scientific rationale to underpin current dosing 
strategies and there remains a great deal of uncertainty about the heterogeneous distribution of dose at 
the cellular and tissue levels and the role of direct and indirect effects such as bystander responses. 
Exposure of non-cancerous cells and tissues surrounding the tumours is of concern in all 
radiotherapeutic treatments, due to acute toxicity and the potential for delayed late effects, sometimes 
many years after treatment (23-30). Quantifying the absorbed dose to non-target tissues is an 
important step in evaluating the potential short- and longer-term secondary radiation risks for patients 




is to be used earlier in the treatment schedule. A 
number of dose calculation models have been developed, for example, for calculation of the absorbed 
dose to blood from radiotherapy (32), however the actual or estimated consequences of these are still 
being quantified (33). 
 
Cytogenetic analysis of chromosome aberrations in blood lymphocytes is widely used to estimate the 
dose of ionising radiation received by an individual following a real or suspected radiation 
overexposure, to help inform assessment of future health risks (34, 35). The dicentric assay is the 
most common method of biological dosimetry, not least due to the high radiation specificity and low 
interindividual variation between yields of dicentric chromosome aberrations (34). In so called 
criticality situations of mixed field neutron and gamma exposures after nuclear reactor incidents, 
where individuals are irradiated by both high-LET and low-LET sources, a model for emergency 
exposure situations has been designed to estimate external doses for the individual exposure 
components (35). Although originally designed for mixed neutron:gamma exposures, for medical uses 












readily derived from patient treatment plans. Meaning that this approach can be applied to calculate 
alpha and X-ray doses in cases of mixed exposures. Complex chromosome aberrations are useful 
biomarkers of LET (36), and their identification in exposed individuals could provide another 
approach for estimating the doses from mixed exposures and, thus, to further refine dose estimation 
methods in mixed exposure scenarios. 
ADDRAD is an approved (NHS REC 15/NI/0074) phase I/ II clinical trial which seeks to address the 
potential benefit of treating metastatic hormone sensitive prostate cancer patients with androgen 
deprivation therapy in addition to 6 cycles of [
223
Ra]RaCl2 and intensity modulated radiotherapy 
(IMRT) to the prostate and pelvic lymph nodes which has recently reported its first clinical data 
showing good response and minimal toxicity (37). This patient group therefore presents a unique 
opportunity to address important radiobiological research questions pertaining to the doses and 
cellular and tissue level damage associated with internal 
223
Ra exposure combined with IMRT. In this 
study, we describe the use of 24-colour whole chromosome painting (multiplex fluorescence in situ 
hybridisation, M-FISH) applied to blood samples taken from the ADRRAD cohort of patients, to 
quantify the patterns of chromosome exchange complexity, with the aim of discriminating damaged 
cells from each component radiation type and estimating absorbed radiation dose. In addition, patient 
specific information is used to calculate absorbed doses to blood on the basis of three different 
established or adapted models, and the dose estimates are compared, with the overall aim to further 
understand the uncertainties involved in dose estimation in this mixed radiation exposure scenario. 
 
2. Methods 
2.1. Physically derived blood dose estimates 
 
The absorbed blood dose per fraction (Db) was estimated using data from 13 recruited mCRPC 
patients. [
223
Ra]RaCl2 was administered over 6 cycles (C1-C6), comprised of one intravenous 




Ra (38) (Figure 1). As part of the treatment, 
IMRT is received during the first 7.5 weeks, coinciding with two [
223












treatment plan for ADRRAD targets the prostate with a dose of 74 Gy, with 60 Gy delivered to lymph 
nodes. IMRT was delivered in daily fractions of 2 Gy to the prostate and 1.6 Gy to the lymph nodes, 
the latter as a concomitant boost. Individualised patient treatment schedules are outlined in 
supplementary Table 1. The absorbed dose to the blood was estimated for 223Ra based on its 
pharmacokinetic properties, and the IMRT dose by two simple blood dose models originally derived 
by Moquet et al. (32) with modifications as described.  
[Insert Figure 1] 
 
 
2.1.1. Pharmacokinetic derived absorbed blood dose of 223Ra 
 
In the ADDRAD trial, [
223
Ra]RaCl2 was administered at an activity  of 55 kBq kg
-1
 of total body 
weight. Following this, the radionuclide will clear from the blood by 24 h. Previous studies identified 
the amount of 
223
Ra in the whole blood volume at varying time points within 24 h of administration 
(12, 39-41). The median percentage of circulating 
223
Ra was averaged at timepoints of 15 min, 4 h and 
24 h between all studies reporting median values with upper and lower ranges (39-41). This gave 
estimates for the percentage of radium in the blood of 22% after 15 min (9-28%), 3% (1.3- 4.95%) 
after 4 h and 0.8 % (0.37-1%) at 24 h. This information was used to estimate the physical absorbed 
dose to the blood by circulating 
223
Ra. 
Firstly, the total activity of 
223
Ra present in the blood was estimated at each timepoint. This was 
determined by multiplying the initial injected activity of radium by the estimated percentage of 
223
Ra 
remaining in the blood and the decay constant of 
223
Ra, 7.02 × 10-7 s-1 (42). The rate of energy 
deposition was then calculated using the energy release for each decay of 
223







Bi) (43), with the total α-particle energy release estimated to be 
4.30 × 10-12 J. Finally, the dose rate to blood was calculated by dividing this rate of energy deposition 
by the mass of blood of the patient, which for this work was estimated using 75 mL of blood per kg 












The absorbed dose rates were then plotted as a function of time following injection, and the area 
under the curve was calculated (GraphPad Prism 9; GraphPad Software; computed using trapezoid 
rule) to estimate the patient specific dose delivered to the blood for the first 24 hours of each 
treatment cycle. As less than 1% of the activity remains at 24 h post-irradiation, it was assumed that 
the additional dose deposited from 24 h to t= ∞ was negligible. The uncertainty on the 
223
Ra absorbed 
blood dose estimates was dominated by the uncertainty in the amount of circulating 
223
Ra at each time 
period, which, as discussed below, could be up to 50% (39-41). 
 
2.1.2. IMRT blood flow model 
 
For this part of the work, data was assessed from 13 ADDRAD patients, for whom treatment plan and 
patient specific data were available. The blood flow model (BF) enabled estimation of dose within the 
high dose organ area. The absorbed blood dose per fraction (DB) was estimated as follows:  
DB= Df (V95 ÷ VB)             (Equation 1) 
Where DB was absorbed dose to blood per fraction, Df was the prescribed dose per fraction, V95 
represents the high dose volume and VB was the total blood volume. 
Two variates of the model were used: BF1, which was applied as per Moquet et al (32) which 
estimates VB by assuming 75 ml of blood per kg and, BF2 which uses the static volume of blood in the 
prostate and lymph nodes for VB, estimated by calculating a scaling factor between the whole-body 
volume and the area irradiated (prostate and/or lymph nodes) on the basis of treatment plan 
information. This scaling factor was then applied to the whole-body blood volume estimates to 
achieve a static blood volume for prostate and lymph nodes. In both cases, DF and V95 were taken from 
the treatment plans. The uncertainty on VB and V95 was estimated to be on the order of 10%, and the 
uncertainty on Df can be estimated on the basis of Moquet and colleagues to be up to 20%. Hence a 













2.1.3. IMRT CT plan model 
 
For this part of the work, data from 13 ADDRAD patients was assessed, for whom treatment plan and 
patient specific data were available. The CT planned volume (CTPV) absorbed blood dose model 
enables dose estimation of both high and low dose areas. The CT volume mapped for each patient was 
utilized to calculate a scaling factor for each patient relative to whole-body volume, with whole-body 
volume being calculated based on the average patient weight (kg) over the course of treatment (44). 
For the following dose models, the whole CT volume was considered within the CTPV1 along with a 
high dose volume only CTPV2. Utilizing the CTPV1 model, the whole-body mean dose was 
estimated, and it was assumed the blood volume had also received this. Firstly, a scaling factor, S, 
was estimated as the ratio between the CT plan volume and the whole-body volume. The following 
was then applied to estimate the absorbed blood dose per fraction: 
DB = (DPB ÷ NF) ÷ S           (Equation 2) 
where DB was the absorbed dose to blood per fraction; DPB was the mean dose in Gy to the body 
volume covered by the CT scan (specific to each patient, taken from the treatment plans), NF was the 
number of fractions of radiotherapy and S was the patient specific scaling factor. A further estimate, 
CTPV2, was performed in the same manner but in this case firstly calculating the average dose per 
fraction for prostate and lymph nodes, and then calculating a scaling factor based on their volume 
compared to the whole-body volume. 
The error associated with the plan volume was considered to be on the order of 1-1.5%. The clinical 
upper acceptable limit in dose delivery to the treatment plan was within 3%, as anything greater than 
this would trigger re-calibration of dose planned area. The scaling factor was estimated from whole 
body volume which was estimated by assuming that 1.01 g of human body mass fits within 1 cm
3
 and 
that the tissue density within the target volume was consistent with this for the scaling factor 
estimation, with an error within 1%. The total error associated with CTPV estimations was considered 












2.2. M-FISH dicentric quantification 
2.2.1. Sample collection  
 
Whole blood was received from 5 male patients recruited onto the ADRADD trial (EudraCT 2014-
00273-39) with full informed consent (NHS REC 15/NI/0074) at The Belfast Health and Social Care 
Trust. Blood samples were drawn into lithium heparinised anticoagulant tubes, once every 4 weeks, 
immediately prior to the first (C1) and then within 24 h prior to each subsequent (C2-C5) 
[
223
Ra]RaCl2 administration (Figure 1). The samples were then shipped at room temperature for next 
day delivery to Brunel University London. Upon arrival, the samples were processed and whole blood 
stimulated to divide to enable the collection of 1
st
 in vitro cell division metaphase cells for cytogenetic 
assessment, as described below.  
2.2.2. Cell culture  
For each sample, 0.4 ml of whole blood was used to inoculate 2.6 ml of freshly prepared 
media (PBMAX Karyotyping Medium (ThermoFisher, Cat. Number 12557021) supplemented with 
0.5 µg/ml purified phytohaemagglutinin (PHA) (ThermoFisher, Cat. Number R30852801), 10µM 5-
bromo-2'-deoxyuridine (BrdU, Sigma-Aldrich Cat. Number 19-160), 10 µl/ml heparin (Sigma-Aldrich 
Cat. Number 9041-08-1) and cultured in a humidified incubator at 37°C (95% air/5% CO2), at a 45° 
angle, and with the cap left slightly open to allow gaseous exchange. Cultures were set up to 
maximise the yield of 1
st
 cell division of peripheral blood lymphocytes (PBLs) and harvested using 
standard cytogenetic techniques after a total of 50-60 h. To arrest cells at the metaphase stage of the 
cell cycle, 50 μl/ml of Colcemid KaryoMAX (ThermoFisher, Cat. Number 1521012), a tubulin 
inhibitor, was added 4 h prior to harvest. After this time, the cultures were centrifuged at 200g for 10 
min and the cell pellet re-suspended before the addition of 0.075M KCl hypotonic solution (Fisher 
Scientific Cat Number10575090) for 8 min at 37°C. Cells were then centrifuged at 200g for 10 min 
and fixed in 3:1 methanol (Thermo Fisher Catalogue Number 15654570) acetic acid (Thermo Fisher 
Catalogue Number 1743468) on ice. The fixation process was repeated until the samples appeared 












2.2.3. Harlequin stain  
 
Fixed chromosome preparations were dropped onto clean, grease-free slides and assessed for 
metaphase quality. Harlequin staining was used to assess the number of 1
st 
division metaphase cells. 
For this, slides were aged on a hot plate for 45 min at 90°C and immersed in Hoescht (Thermo Fisher 
Scientific Cat Number 62249) for 10 min, then transferred to a flat tray and covered in 2x Saline-
Sodium Citrate (SSC) (Thermo Fisher Cat Number 15557036), before being exposed in UV box to 
1.0 J/cm
2
 for 1 h. After exposure slides were washed with distilled water twice and air dried. Treated 
slides were stained in 5% Giemsa (VWR Cat Number 350864) for 4 min, removed and rinsed with 
distilled water. Once dry, the slides were mounted with coverslips with 4 drops of DPX (Fisher 
Scientific Cat Number 15538321). Slides were scored using brightfield microscopy with oil 






 division cells was determined based upon 
the chromatid staining patterns (45, 46). Samples with ≤ 5% 2
nd
 division cells were assayed by M-
FISH. 
2.2.4. Multiplex fluorescence in situ hybridisation (M-FISH) 
 
M-FISH was carried out utilizing 24XCyte staining probe (Metasystems Probe Cat NumD-
0125-600-DI) as per manufacturer protocol. Patient slides were selected from 5 patients according to 
metaphase spread quality and whether samples containing ≤ 5% 2
nd
 division cells, a minimum of 3 
patient slides were painted per cycle.  In brief, slides were incubated in 2xSSC at 70℃ (±1℃) for 30 
min. After this time, the cooled slide was transferred into 0.1xSSC at RT for 1 min. Chromosomes 
were then denatured in 0.07 NaOH at RT for 1 min followed by 1 min incubation in 0.1xSSC, 
followed by 2xSSC at 4℃, and then dehydrated through immersion in a series of alcohol solutions of 
ascending strength (70%, 95% and 100%). The 24Xcyte probe was denatured by incubating at 75℃ 
(±1℃) for 5 min, placed on ice briefly and then incubated at 37℃ for 30 min. The probe was overlaid 
on to the slide and left to hybridize in a humidified chamber at 37℃ (±1℃) for 2-3 days. Slides were 












Tween20) for 30 secs. For counterstaining, the slide was rinsed in double distilled water and left to air 
dry before application of DAPI/antifade and sealing. 
Slides were visualised utilizing 8-position Zeiss Axioplan 2 microscope containing individual 
filter sets for 24XCyte probe cocktail plus DAPI (FITC, Spectrum Orange, Texas red, Cy5, DEAC 
and DAPI). Metaphase cells were imaged under x63 oil immersion and captured by Cool Cube driven 
by Metafer4 version 3.14.191 software. The image files were exported and karyotyped in ISIS version 
5.8.11. 
2.2.5. Chromosome aberration classification 
 
A cell was classified as being apparently normal if all 46 chromosomes were present and contained 
the appropriate fluorophore combination along their entire length. Only metaphase cells with good 
fluorochrome staining were selected for analysis in cells containing ≥ 43 chromosomes. Chromosomal 
aberrations were identified by colour junctions along the length of each individual chromosome 
and/or by the presence of chromosomal fragments (Figure 2b). A chromosome interchange involving 
2 breaks in 2 chromosomes was categorised as a simple exchange, and further classified as a 
reciprocal translocation or dicentric. Ring chromosomes, which involve 2 breaks in one chromosome 
were also classed as simple (47). Exchanges involving 3 or more breaks in 2 or more chromosomes 
were classed as complex and assigned the minimal number of breaks, arms and breaks involved 
(CAB) (48). Chromosomes having breaks only, not involving any additional chromosomes, were 
classed as chromosome breaks. When classifying cells with multiple aberrations, all aberrations were 
recorded as independent events and the chromosomes involved identified. Where homologous 
chromosomes were involved, efforts were made to establish whether the homologues were in the 
same event or in different independent events, mainly by consideration of chromosome length (49). 
All exchanges were recorded as either complete (all break-ends re-joined), true incomplete (where 
one or more break-ends fail to find an exchange partner) or one-way (where one or more elements 
appear to be missing) (50, 51). The potential transmissibility of exchanges was also recorded, where a 












e.g. dicentric or acentric fragments. Each independent complex event was also determined to be 
transmissible or non-transmissible and the presence of insertion-type rearrangements were noted (49). 
Metaphase spreads were categorised as stable only if all the exchange events detected within that 
spread were classified as stable. Unstable complex chromosomal exchanges containing polycentric 
chromosomes were broken down in to their dicentric equivalents whereby each additional centromere 
within a chromosome structure constituted a dicentric equivalent (dicentric equivalent event = n 
centromere -1) (Figure 2). 
2.3. M-FISH dicentric assay dose estimation 
 
2.3.1. Mixed field absorbed blood dose ratio 
 
For this part of the work, M-FISH analysis was carried out n=5 individuals with a minimum of n=3 
patient samples processed for C2-C5. The 
223
Ra:IMRT ratio was estimated in two ways. Firstly, by 
physical dose estimation and secondly, from categorising cells based on the complexity of 
chromosome exchange observed. For the physical dose ratio, the absorbed blood dose was calculated 
independently for [
223
Ra]RaCl2 and IMRT (section 2.1) for each exposure and was summed over the 
4-week time period prior to each sample being taken. The average absorbed blood dose per cycle was 
estimated by averaging the absorbed blood dose across all 13 patients for all treatment cycles. For the 
dose ratio the overall treatment plan was used (Figure 1), not the patient specific plan adaptation. 
Therefore, C2 relates to the response to one injection of [
223
Ra]RaCl2 and 20 IMRT fractions, C3 
relates to two injections of [
223
Ra]RaCl2 and 37 IMRT fractions, with C4 and C5 each including the 
additional [
223
Ra]RaCl2 only administrations. Summing these gives the total absorbed blood dose of 
[
223
Ra]RaCl2 and IMRT delivered at each time point from C2 to C5. For the M-FISH derived ratio (M-
FISHLET), cells containing at least one complex chromosome exchange were classed as being 
damaged by the traversal of high-LET α-particles from the 
223
Ra while cells containing only simple 
chromosome exchanges, as from IMRT (section 2.2.5). The ratio of cells containing at least one 
complex chromosome exchange to cells containing simple exchanges only was therefore a pseudo 
ratio for 
223













2.3.2. Dicentric absorbed blood dose estimation 
 
The dicentric assay traditionally utilizes Giemsa staining where chromosomes are evenly stained in 
one colour, (Figure 2a), thus enabling the identification of chromosomes containing more than one 
centromere along with any associated acentric fragment. In this study, dicentrics were quantified from 
M-FISH painted metaphase cells (Figure 2b and c). 
 
[Insert Figure 2] 
 
Dose estimation was first carried out utilizing the dicentric equivalent frequency as determined by M-
FISH. For the IMRT, the 
60
Co calibration curve of Lloyd and colleagues, 1986, was used (52) where 
whole blood was irradiated in vitro utilizing a 
60
Co source with dose range of 0-5 Gy. The dicentric 
yield was entered into Dose Estimate V5.2 (53) with the following coefficients α= 0.0756 ± 0.0031, 
β= 0.0149 ± 0.0060 and C= 0.0004 ± 0.0009 (52). This being a well-established calibration curve, it 
has been utilized in many exposure scenarios for γ-ray and X-ray dose estimation by Public Heath 
England and was judged to be the most comparable curve in terms of type and energy of radiation 
exposure. As there is currently no 
223
Ra calibration data, a calibration curve based on a 
239
Pu, which 
emits α-particles of a similar energy to 
223
Ra (5.16 MeV per α-particle), was selected. The 
239
Pu 
calibration curve of Purrott et al., 1980, (54) was used, the curve coefficients were: β= 0.3696 ± 




Pu does differ, however, due to the 
perceived lack of risk of a radiation accident involving alpha exposures and the complexity of the 
experiments, alpha curves for biodosimetry are rare. This curve was established by irradiating whole 
blood with 
239
Pu in the range of 0-1.6 Gy. It is important to note, however, that in this study, the likely 
non-homogeneous, partial body, nature of both the 
223
Ra and IMRT exposures beyond the treatment 
plan details, was not further considered, neither was the microdosimetric heterogeneity of radium in 
areas of high bone turnover, and thus this represents a key source of unquantified uncertainty. This 












calculate the absorbed blood dose in this mixed exposure scenario, the “criticality” model was used 
(35). In brief, all aberrations were firstly assumed to be attributed to 
223
Ra and from the dicentric 
equivalent yield the dose was estimated. The absorbed blood dose ratio (
223
Ra:IMRT) calculated 
according to section 2.3.1. was then used to estimate the IMRT dose and then the gamma calibration 
curve used to estimate the dicentric equivalent yield. This IMRT yield was then subtracted from the 
total yield to give a ‘new’ 
223
Ra dicentric equivalent yield. This iterative process was repeated until 
self-consistent estimates were obtained. 
 
2.4. Other statistical analysis  
Statistical analysis was performed using GraphPad Prism 9 (GraphPad Software). Descriptive 
statistics are presented as mean ± SE for pooled data. Standard propagation of errors was applied to 
estimate the uncertainty in the derived dose estimates. Normality testing indicated ANOVA was 
appropriate in order to test for differences in aberration frequencies between treatment rounds and for 




3.1. Estimating the blood dose from the treatment schedule 
 
Patient data related to the planned treatment for 13 patients was available for physical dose 
estimation. Table 1 gives the absorbed blood dose per fraction predicted by the BF model, estimated 
for each patient for the prostate, lymph nodes, and total high dose region combined. The majority of 
the absorbed blood dose was estimated as being from lymph node exposure, due to the larger volume 
of irradiation for this tissue (BF1). The total prostate-only absorbed blood dose was found to be in the 
range of 0.880-1.962 Gy by the end of IMRT treatment (30-37 fractions; 37 fractions assumed for 
dose ratio calculations in section 3.3), comparable to the 0.38-1.92 Gy reported by Moquet et al. To 












combining the BF models (BF1P + BF2LN), the cumulative absorbed blood dose was estimated to be 
between 1.131 – 2.717 Gy. 
 
Table 1. BF model. VB blood volume, DB blood dose per fraction. BF1P from BF1 prostate dose 
combined with BF2 LN dose (BF2LN). Patients for whom treatment plan and patient specific data were 
available n=13. Reported estimated uncertainty of 25% for all BF model variants. 
 
 
    



















Total dose DB 
(Gy)  
1  9030 12.9  54.5  0.038 0.132 0.170 0.007 0.045 
2  7615 11.7  56.8  0.041 0.164 0.205 0.010 0.050 
3  6288 9.5  49.2  0.040 0.171 0.212 0.009 0.049 
4  6560 12.2  57.2  0.060 0.231 0.291 0.014 0.073 
5  6461 13.8  63.9  0.056 0.209 0.265 0.015 0.071 
6  6985 10.8  58.9  0.041 0.184 0.225 0.011 0.052 
7  7650 9.4  52.0  0.033 0.149 0.181 0.008 0.040 
8  5700 7.0  32.4  0.032 0.124 0.157 0.004 0.037 
9  6290 11.5  49.1  0.050 0.154 0.204 0.007 0.058 
10  6629 14.0  52.3  0.056 0.171 0.227 0.009 0.065 
11  5559 9.1  48.4  0.043 0.188 0.231 0.009 0.052 
12  7883 7.1  49.2  0.024 0.135 0.159 0.007 0.031 
13  6486 10.2  54.8  0.042 0.161 0.203 0.009 0.051 
 
 
The absorbed blood dose was estimated for the whole CT plan area, including high dose and low dose 
regions (CTPV1) and for high dose regions only (CTPV2) to enable comparison with the BF model.  
Previous CTPV approaches have used a fixed scaling factor of 2.5 with a reported uncertainty of 20%. 
In this work we instead estimated a patient specific scaling factor between 2.08-2.64, with the largest 
deviation from the scaling factor for Patient 10 being 16% smaller than the published 2.5 scaling 
factor. The increased absorbed blood dose CTPV estimates compared to the BF estimates observed 
here are likely to be reflective of the large lymph node irradiation volume (32). To compare the BF 












nodes, termed as CTPV2. To do so, a scaling factor for each component as detailed for BF2, was used. 
The resulting absorbed blood doses for CTPV2 were found to be comparable to that of BF2 within the 
uncertainty estimates (Table 2). The average absorbed blood dose per fraction of IMRT was estimated 
as 0.101 Gy for CTPV1 and 0.016 Gy for CTPV2 (average n =13 patients), each with an estimated 
uncertainty on the order of 6%. 
 
BF1 and CTPV1 cannot be directly compared as they use different irradiation volumes. The BF1 model 
assumes the blood flow within prostate and lymph node regions was identical and in doing so, 
it appears to significantly overestimate the lymph node blood volume. On the basis of this and the 
simple nature of the other model assumptions, this method likely has the largest uncertainty. 
Accordingly, only CTPV1 and CTPV2 are considered further as these models represent an estimate of 
combined absorbed blood dose for high dose regions and low dose regions (CTPV1) and high dose 
regions only (CTPV2). Supplementary Table 1 details the patient specific injected activities and CT 
planning volumes. Table 2 shows the individual absorbed blood dose estimates for each 
223
Ra 
administration, and the IMRT absorbed blood dose estimates for each fraction. The average 
223
Ra 
absorbed blood dose per treatment cycle was 0.012 ± 0.002 Gy. The estimated 
223
Ra absorbed blood 
dose per fraction was not found to be statistically different between patients (P= 0.097). To estimate 
the 
223
Ra absorbed blood dose per treatment cycle, the median values of the activity kinetics reported 
in the literature were utilized. Based on the highest and lowest limits reported for each timepoint the 
223
Ra blood dose estimates per treatment cycle could vary by up to 50%. This value being reported as 
a conservative estimate of uncertainty for dose estimates, with more work needed to quantify the 
variations between patient clearance.  
 
Table 2. Physically derived absorbed blood dose, in Gy. 
223
Ra absorbed blood dose was representative 
of an average dose to the blood during localization period. The absorbed blood dose after all treatment 
cycles was calculated for n=6 injections with the exception of Patient 5 where n=5. IMRT absorbed 












factor estimated from patient body volume derived from average weight during treatment. Patient 
numbers n=13 patients for whom treatment plan and patient specific data were available. 





Patient ID DB (Gy) CTPV1 DB (Gy) CTPV2 DB Dose(Gy) 
1 0.0116 0.105 0.013 
2 0.0114 0.104 0.015 
3 0.0116 0.101 0.016 
4 0.0118 0.113 0.022 
5 0.0116 0.100 0.020 
6 0.0116 0.112 0.017 
7 0.0117 0.092 0.014 
8 0.0118 0.095 0.012 
9 0.0117 0.089 0.015 
10 0.0115 0.113 0.017 
11 0.0114 0.108 0.018 
12 0.0116 0.094 0.012 
13 0.0114 0.088 0.015 
 
 
3.2. Frequency and type of chromosome aberration in ADRADD patients 
 
M-FISH analysis was carried out on blood samples received from 5 patients for C1-C5. The control 
samples of all 5 patients were analysed and following this a minimum of 3 patients were analysed per 
treatment cycle. The background frequency of chromosomal aberrations was found to be within the 
expected normal range for individuals in the 50+ age bracket (55, 56). Specifically, frequencies of 0.0, 
0.024 ± 0.011 and 0.020 ± 0.009 were observed for simple dicentrics, reciprocal translocations and 
break-only aberrations, respectively (sample C1; pooled for 5 patients). One cell containing an 
unstable complex rearrangement was found in Patient 2 (0.004 ± 0.004), for which the origin was not 
clear.  
Simple chromosomal exchanges were observed to significantly increase in frequency between C1 and 
C2 (0.024 ± 0.011 to 0.319 ± 0.042 (P < 0.001)) and further at C3 to 0.484 ± 0.042 (P < 












(C3-4, P= 0.966 or C4-C5, P= 0.996), suggesting the majority of simple aberrations formed early in 
the treatment regime persist over the period sampled, and/or the induction of new aberrations was 
balanced by cell death of unstable (e.g. dicentric) types. The frequency of complex exchanges 
increased from 0.058 ± 0.016 at C2 to 0.174 ± 0.022 at C3 (P = 0.007), rising further to 0.265 ± 0.037 
at C4 and 0.210 ± 0.030 at C5 (Supplementary Table 2).  
In terms of classification of complexity, the frequency of damaged PBLs assigned to each exposure 
type (
223
Ra or IMRT) was reported in Figure 3 and Table 3. This categorisation was based upon the 
presence or absence of a complex chromosome exchange and shows that the majority of damaged 
PBLs sampled, with combined IMRT and 
223
Ra contained mostly simple exchanges only at C2 (cells 
containing simple exchanges 0.204 ± 0.025 and containing at least one complex exchange 0.050 ± 
0.014, P < 0.001) and C3 (0.243 ± 0.021 and 0.150 ± 0.018, P = 0.006). After this time, when patients 
continue to receive 
223
Ra only, the fraction of damaged PBLs with at least one complex exchange 
increased. In the 
223
Ra only cycles, no significant difference between cells containing a simple 
aberration and those containing at least one complex exchange was observed (C4 P = 0.992, C5 P = 
0.558).  
 
[Insert Figure 3] 
 
3.3. M-FISH dicentric assay absorbed blood dose estimates 
 
The absorbed blood dose ratios were estimated for C2-C5, this was equivalent to 4 intravenous 
injections of 
223
Ra and completed IMRT schedule of 37 fractions by C5. For the physical dose ratio, 
this was based on the average absorbed blood dose per fraction across all 13 patients for both the 
IMRT and 
223
Ra dose. The M-FISHLET ratios described in section 2.3.1, was obtained from blood 
samples received from 5 patients with a minimum of 3 patient samples analysed per cycle. The 
absorbed blood dose ratios for all models can be seen in Table 3. Applying these blood dose ratios to 












methods were derived from the physical absorbed blood dose estimates as per method section 2.1. 
with CTPV1 estimating the absorbed blood dose across the planned volume including both high and 
low dose volumes whilst CTPV2 including the high dose regions only. The M-FISHLET absorbed 
blood dose was instead estimated from the ratio of cells consistent with high LET exposure (
223
Ra) 
and low LET exposure (IMRT). 
 
Table 3. Absorbed blood dose ratios. M-FISH derived ratio based on the complexity of cellular 
damage with 
223
Ra assigned cells to include those with at least 1 complex exchange and, IMRT 
assigned cells defined as containing only simple exchanges. Frequency per total cells scored pooled 
per cycle, with calculated SE. DB per cycle of patient average (n=13), complexity of cellular damage 
from pooled patient data (n=5). 
 
 
Cellular classification  DB per cycle 
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The absorbed blood dose estimates from the CTPV models suggest the dose after 20 IMRT fractions, 
measured at C2 (Table 4), was between 1.327 ± 0.115 Gy and 1.395 ± 0.115 Gy. The M-FISHLET 
method was found to be in similar range at 0.956 ± 0.114 Gy at C2. The IMRT absorbed blood dose 
after the end of fractionation (C3 assuming 37 completed fractions) was estimated for CTPV1 as 2.148 















Ra absorbed blood dose at C2, the CTPV1 and CTPV2 were found to be 0.008 ± 0.025 and 
0.048 ± 0.032, both lower than the M-FISHLET estimate of 0.150 ± 0.046 Gy. For C3 the
 223
Ra 
absorbed blood dose estimated from CTPV methods was between 0.013 ± 0.025 and 0.082 ± 0.033 
Gy (CTPV1 and CTPV2 respectively) with the M-FISHLET absorbed blood dose estimated at 0.719 ± 
0.073 Gy. By the final sample point studied here (C5), the absorbed blood dose from 
223
Ra was 
estimated as 0.024 ± 0.027 Gy by CTPV1 and 0.141 ± 0.042 Gy for CTPV2 with the M-FISHLET 
absorbed blood dose estimate at 0.665 ± 0.080 Gy (see Figure 4). 
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2 











































































































































































































































































Table 4. Absorbed blood doses during treatment (Gy) calculated on the basis of CTPV1, CTPV2 and 
M-FISHLET models. Patients sampled during treatment cycles were coded and identifier number (ID) 
assigned, n=5 patients were assayed by M-FISH to determine the dicentric equivalent yield. The 
absorbed blood dose was calculated with use of dicentric assay for each patient with the dose ratios 
estimated from CT plan and M-FISHLET derived models. The SE was reported for the absorbed blood 
dose estimation, this being the largest uncertainty for M-FISHLET dose estimation. CTPV1 and CTPV2 
reported SE of absorbed blood dose estimation with a propagated conservative uncertainty estimated 














In the future, α-particle emitters, such as 
223
Ra, alone or in combination, are likely to be adopted in the 
treatment of a wide range of cancers, contributing to more targeted, personalised medicine with the 
potential to impact a large number of patients (17, 57, 58). To date, however, there are only limited 
studies using biological endpoints which seek to understand the biological action of 
223
Ra in vivo in 
humans, to improve the optimal delivery of these and, to minimise the risk of adverse effects through 
radiation exposure of normal tissues (59-63). Quantifying the absorbed blood dose delivered from the 
treatment is an important step in maximising clinical efficacy and evaluating radiation risks, estimates 
of which are currently based on population studies (31). In this study, whole blood was sampled from 
patients recruited onto the ADRRAD trial (37). The treatment includes a planned mixed field 
exposure from daily IMRT fractions, 37 x 2 Gy to prostate with concomitant boost (37 x 1.6 Gy) to 
lymph nodes, over a period of 7.5 weeks, together with 6 intravenous injections of [
223
Ra]RaCl2 over a 
period of 20 weeks. Dose estimation for non-targeted tissues in mixed exposure scenarios is 
challenging. To account for the mixed field nature of the treatment, existing models were used to 
determine the ratio of the component radiation types. Additionally, a new approach (M-FISHLET), 
based on the ratio of cells containing damage consistent with high-LET exposure (complex 
chromosomal exchanges) and low-LET exposure (simple exchanges), was used as a pseudo ratio for 
223
Ra:IMRT absorbed blood dose. 
223
Ra exposure was dictated by its unique pharmacokinetic properties and its ability to target calcium-
dependent bone turnover. Once intravenously administered, 
223
Ra is rapidly cleared through the 
gastrointestinal tract and the remainder through the kidneys (39, 41). Previous studies on rodents 
found minimal uptake of 
223
Ra in non-targeted areas such as kidneys and the spleen (13, 64) with the 
highest absorbed doses being observed in humans in neighbouring sites of target bone metastases, 
including osteogenic cells and the red bone marrow (17, 19, 20). Here, the 
223
Ra absorbed blood dose 
was estimated from the injected activity using an existing clearance model, based on the quantity 
of 
223












uncertainty for the 
223
Ra physical absorbed blood dose estimations per cycle was based on the errors 
associated with the injected activity, patient weight and clearance models used. The injected activity 
per patient was estimated from the known activity in the syringe prior to administration and the 
remaining activity after injection, the error associated with this was considered negligible. Patient 
individual weights were found to fluctuate during treatment by 8% (up to 6.2 kg lost by C6). 
Therefore, the 
223
Ra absorbed blood dose was estimated for each chosen timepoint from the data 
available at the specific treatment cycle rather than an average across treatment along with the median 
values of 
223
Ra in the blood at each timepoint (averaged between reported studies). The average 
absorbed blood dose per cycle was estimated as 0.012 ± 0.002 Gy (average of Table 2 as per methods 
2.3.1). In order to estimate the uncertainty for the clearance model, the reported ranges in terms of 
upper and lower range limits were taken from the literature (39-41) with a variation from the median 
of up to 50%. The average uncertainty on the delivered 
223
Ra activity was thus estimated to be as high 
as 50%. The additional absorbed blood dose delivered after 24 h period was not considered in this 
model. Although the additional absorbed blood dose is likely to be within the 50% uncertainty 
described, it may not be implicitly negligible and does form an additional contribution to the 
uncertainty not quantified here. 
The physical absorbed blood doses reported here are higher than those reported by Stephan et al using 
224
Ra and in a similar range to those reported by Schumann et al for 
223
Ra (65,66). The decay kinetics 
and energies of 
224
Ra are broadly comparable to those of 
223
Ra, however, as Stephan and colleagues 
report, there are a number of limitations associated with the application of the ICRP 67 model (67), 
including the lack of information regarding the local distribution of the activity. The aim of the 
223
Ra 
clearance calculations in this work was not to test the ICRP model, rather, to provide a very simple 
kinetic method for validation of the newly proposed biological absorbed blood dose estimation 
methods presented. Nevertheless, further work is required to assess the most appropriate means of 













IMRT utilizes conformal beams to accurately target a designated area minimising exposure to non-
target organs/tissues. Unlike 
223
Ra, this treatment is tailored to the disease burden of each patient with 
the number of fractions, dose and area covered dependent upon patient specific information 
(Supplementary Table 1). Using this, estimates were carried out employing two models previously 
described by Moquet and colleagues, which were designed to provide a relatively simple assessment 
of RT doses (32). The first model, the blood flow model (BF), was based on the time taken for blood 
to flow through the high dose planned area. Moquet et al., assumed that 6 L of whole blood flows 
through the high dose region within a 1-min IMRT exposure time (32). For this study, individual 
patient weights were available, therefore blood volume was more accurately estimated by assuming 
each kg of body weight contains 75 ml of blood (68), (BF1). The absorbed blood dose per fraction was 
then estimated to  range between 0.159-0.291 Gy and this was equivalent to a cumulative dose of 
5.872-8.715 Gy at IMRT treatment completion (see supplementary table 1). Although lymph nodes 
are in proximity of vascularized tissue, they do not circulate blood, instead they circulate lymph fluid. 
BF1 was therefore likely to overestimate the lymph node absorbed dose. The fluid shift within lymph 
nodes is approximated to ~4 L per day (69) which may be negligible during treatment. To model the 
lymph node exposure, the static absorbed blood dose was calculated (BF2) using similar principles, 
subsequently scaled down to lymph node planned volume. Lymph node absorbed blood dose per 
fraction represents 0.004-0.015 Gy which was equivalent to 0.152-0.508 Gy by IMRT completion 
(patient individualised schedule). This BF2 model was likely to be a more accurate representation 
of static PBL irradiation in this tissue that may then be filtered to the circulatory system. By 
combining the two models, the cumulative absorbed blood dose to high dose volume likely was 
between 1.131-2.470 Gy by completion of individualised IMRT schedule. Neither of these models 
consider the low dose regions that are also exposed during treatment; therefore, so both will 
underestimate the total blood dose. The original work of Moquet and colleagues (32) was relatively 
simple and requires further validation to ascertain exposure circumstances in which such models can 
be applied. In this study, patient specific data was utilised to refine these models, with limited success. 
The uncertainties in CTPV absorbed blood dose were derived by propagation of the uncertainties 












planned volume (considered minimal at 1-1.5% variation), the dose to planned volume and the 
estimated scaling factors. The dose to the plan region was expected to have an uncertainty of less than 
3%, based on published estimates of the upper bound of inter-treatment dosimetric uncertainty (70) 
and greater errors would be detected by treatment QA and trigger re-planning and re-validation. To 
estimate the whole-body volume, it was assumed that 1.01 g of human body mass fits within 1 cm
3
 
and that the tissue density within the target volume was consistent with this for the scaling factor 
estimation, with an error within 1%. The total error associated with CTPV estimations was considered 
to be 6%. It is important to note, however, that the estimates of uncertainty are themselves uncertain 
and further work is needed here to better understand how patient specific data can contribute to such 
estimates. In addition, more detail with respect to beam-on times are required to improve the BF dose 
model, in particular, for larger dose volumes, therefore, despite its use previously, this model was not 
considered further.  
To enable the absorbed blood dose estimation by dicentric assay in this mixed (
223
Ra and IMRT) 
exposure scenario, the absorbed blood dose ratio between each source was estimated per treatment 
cycle. This then facilitated use of the “criticality” dose estimation technique, originally designed to 
separate and quantify neutron and gamma exposures following a nuclear accident or incident (35), but 
here used to assess the IMRT and α-particle absorbed doses, on the basis of either the treatment 
planning information (CTPV ratios), or the categorisation of complexity of aberrations observed using 
M-FISH. The dicentric assay was applied to two separate models, the first utilizing the ratio derived 
from physical models, 
223
Ra clearance and IMRT CTPV models, and the second utilizing the M-
FISHLET ratio based on the categorisation of high LET to low LET exposed cells. The absorbed blood 
dose estimations were carried out for 5 patients for which blood samples were drawn and the dicentric 
equivalent frequency estimated. The CTPV derived ratios assume that IMRT induced aberrations 
accumulated in the circulatory blood pool by C3 are not cleared from the peripheral pool in the 
following C4 and C5 treatment cycles and similarly for the 
223
Ra, it was assumed the aberrations 
accumulate through treatment with no clearance. This results in a plateau of IMRT dose for CTPV1 as 
the dose ratio was based on a large IMRT component with a small 
223












model was based on high dose regions areas, the IMRT estimated dose was lower than CTPV1, 
therefore when expressed as a ratio with 
223
Ra, this assumes a higher proportion of absorbed blood 
dose to be attributed to
 223
Ra, which decreases the estimated dose for C4 and C5. The dicentric assay 
was estimated from the ratio of physical 
223
Ra and CTPV dose estimates with a conservative error of 
50% being attributed to the 
223
Ra dose, this was considered to be the largest uncertainty. Future 
studies will aim to reduce this uncertainty by increasing the number of patients in the study and by 
including later timepoints.  
The M-FISHLET model was based on the chromosomal aberration spectrum in PBL sampled 4 weeks 
after each [
223
Ra]RaCl2 administration. Following IMRT completion, the dose was estimated at 1.167 
± 0.092 Gy. This was based on the assumption that all IMRT induced aberrations would be of simple 
type while 
223
Ra aberrations were of complex type. As a larger proportion of cells containing complex 
aberrations than simple chromosomal aberrations was observed, this was reflected in the dose ratio. 
Accordingly, the dose attributed to 
223
Ra was proportionally larger than that attributed to IMRT. The 
resulting IMRT absorbed blood dose estimated by M-FISHLET was therefore lower than both CTPV 
dose estimates. The physically derived 223Ra estimates were representative of the period taken for 
223
Ra to clear from the blood. Due to the sampling schedule being every 4 weeks, it cannot be 
excluded that absorbed dose from 
223
Ra was also received by circulating PBLs in the vicinity of 
metastatic sites, especially as metastatic sites tend to be highly vascularized (71-73). The M-FISHLET 
absorbed blood dose estimates may better account for this, with the 
223
Ra dose by C5 estimated to be 
0.665 ± 0.080 Gy. This estimate was significantly larger than CTPV1 0.024 ± 0.027 Gy and CTPV2 
0.141 ± 0.042 Gy. The largest uncertainty in the M-FISHLET absorbed blood dose estimation was 
found to be also in C2 whereby the variation in the frequency of cells consistent with IMRT exposure 
(cells containing simple aberrations only) was up to 13% and for those consistent with 
223
Ra exposure 
of up to 28%. The error from the calibration curve used was estimated to be 12 and 23% for IMRT 
and 
223
Ra absorbed blood dose estimates, respectively. The total propagated error on absorbed dose 













In this study, the complexity of chromosome exchange observed in PBLs was used as a biomarker of 
radiation quality (36) from which to make estimates of absorbed blood dose ratio, termed the M-
FISHLET. Based upon principles of radiation track structure and PBL cell geometry (36, 74), all cells 
which contained at least one complex chromosome exchange (75, 76) were categorised as having 
been traversed by high LET α-particles emitted from the 
223
Ra, while damaged cells containing only 
simple chromosome exchanges (reciprocal translocation, dicentrics and rings) were categorised as 
being exposed to low LET radiation from IMRT. Although in vitro studies do show the majority of 
high-LET induced damage to result in complex chromosome aberrations largely independent of dose 
(77-81) it is also the case that the simple exchanges can be directly induced after α-particles of lower 
incident LET (74) and, exposure to low-LET radiation will result in the formation of complex 
exchanges, in a manner strongly dependent upon dose (50, 82, 83). For instance, an increasing 
fraction of complex exchanges of up to 20-40% have previously been attributed to exposure of a large 
target field in IMRT treated prostate cancer patients (84, 85). Therefore, it is likely that IMRT 
absorbed blood dose may be underestimated using the M-FISHLET reported here. Given the potential 
usefulness of this ratio in cases of unknown exposures where physical information is not available, 
further work to determine frequencies of complex exchange occurrence in IMRT only and 
223
Ra only 
treated patients is required. 
As the M-FISHLET absorbed dose ratio and the dicentric quantification was based on cytogenetic 
observations of sampled PBL, the resulting doses estimated will be directly affected by 
haematopoietic cell death and repopulation dynamics. The IMRT dose estimates were found to 
plateau between C3-C5 suggesting cells containing unstable aberrations remain over the time course 
studied. However, IMRT has been shown to significantly decrease the number of PBLs in circulation, 
and therefore the clearance and repopulation dynamics should also be taken into consideration for the 
CTPV models (25, 86, 87). White blood cell counts have been found to increase within 6-8 weeks of 
therapy completion with a significant increase in lymphocyte population after 3 months (26, 88). 
The 4-week period between C3-C4 (after end of IMRT) could provide a sufficient break for 












the frequency of persisting unstable chromosomal events. Newly induced aberrations by subsequent 
223
Ra treatment cycles would then add to this aberrant cell pool. There is also the potential of 
bystander responses playing a role both in cell turnover and aberration formation (89). Further work 




administrations (C6) and follow up samples (up 
to 1 year post start of treatment), together with patient haematological counts, will help elucidate the 
cellular dynamics of damaged PBL. An assessment of the occurrence and type of stable chromosome 
exchange from these samples will also offer the potential to make estimates of absorbed dose 
delivered to the bone marrow. 
In conclusion, in this study we have evaluated a number of absorbed blood dose methods for mixed 
field exposure, in a unique population of patients receiving external beam photons and a systemically 
delivered α-emitter 
223
Ra. We highlight key observations and limitations to establish an approach from 
which we can make dose assessments to better understand mixed field exposures. The models 
presented provide an initial estimation of cumulative absorbed dose received to the blood during 
incremental IMRT fractions and [
223
Ra]RaCl2 injections, all of which move towards assessing patient 
specific dose information for mixed field treatment to help optimise treatment outcomes and minimise 
patient risk in the future.  
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Pictorial abstract. Blood doses were estimated using models of 
223
Ra blood clearance and clinical 
IMRT treatment plans, as well as through a novel application of the M-FISH dicentric assay based on 
markers of high and low LET radiation exposure. 
 
Figure 1. Treatment timeline. IMRT daily fractions for 7.5 weeks. [
223
Ra]RaCl2 was administered 
every 4 weeks for a total of 6 injections. Blood samples were collected at each cycle, with a control 
sample collected at week 0 prior to treatment start (C1). Subsequent blood samples were taken every 4 
weeks just prior to the next [
223
Ra]RaCl2 administration, up to C6. Hence blood samples from C2 and 
C3 are representative of mixed field exposure while C4-C6 are 
223
Ra only. For this study only samples 
up to C5 were analysed.  
Figure 2. Dicentric equivalent scoring. a) 1
st
 division Giemsa stained metaphase imaged under bright 
field microscopy x100 magnification under oil. Chromosome with two centromeres highlighted along 
with acentric fragment b) Pseudo colour processed image painted by M-FISH, captured at x63 
magnification under oil. Complex chromosomal exchange between three chromosomes, dicentric 
chromosome highlighted by red arrow along with other components in yellow. c) DAPI channel of 
same cell (b) highlighting same aberration as a simple dicentric exchange.  
Figure 3. Frequency of cells containing either simple (●) or at least one complex (▲) chromosome 
exchange. Data pooled from 5 patients total, n=3 patients/cycle (C2,3 and 5) and n=4 for C3. Error 
bars represent standard error of the mean for pooled data. 
 
Figure 4. Comparison of 
223
Ra dose estimates. M-FISHLET ratio was implemented in the dicentric 
assay estimates of blood dose for n=5 patients (patient ID 1-5), the estimates for these patients were 
compared across all other models. CTPV1 and CTPV2 calculated from the dicentric assay utilizing the 
physical blood dose estimates by 
223
















0.559 and for CTPV2 Y = 0.115*X + 0.025, R
2
 = 0.600. 
Physical 
223
Ra dose estimated through clearance of 
223
Ra from circulation 24 h post administration. 
Simple linear regression plotted for Y = 0.028*X + 0.012, R
2 
= 0.301. The error associated with the 
physical 
223
Ra was conservatively estimated to 50% and propagated to CTPV1, CTPV2. The error for 
M-FISHLET dose was propagated as 30% for C2 and 14% for C3-C5. 
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